Just a moment, the page is loading...

GSK-104420




A phase II study to evaluate the persistence of measles, mumps and rubella antibodies two years after the single dose primary vaccination in study 209762/151.
Measles, Mumps, Rubella Vaccine
104420
Measles; Mumps; Rubella
Phase 2
This is a follow-up study to 209762/151. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.
June 2015